Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 27, 2017

View Archived Issues

Alzamend Neuro selects consultant to lead path to IND filing for CAO-22W

Amicrobe receives award from CARB-X to support development of Amicidin-beta

1st Biotherapeutics and Neuraly to jointly develop drugs for Parkinson's

MabSpace files Chinese IND for second-generation PD-L1 antibody MSB-2311

Heron Therapeutics' HTX-011 awarded FDA fast track designation

Achaogen submits plazomicin NDA in U.S.

Innovation Pharmaceuticals completes phase II trial of Brilacidin-OM

C12G6 demonstrates broad prophylactic and therapeutic activity in preclinical models of influenza B

Saniona will perform interim analysis of Tesomet study in Prader-Willi syndrome

Clinical results with autologous mesenchymal stem cell neural progenitors lead to phase II MS trial

FDA gives breakthrough therapy designation to valoctocogene roxaparvovec

Results from the ReBUILD study of clemastine fumarate as a remyelinating drug for multiple sclerosis

Vaxart reports results from phase II study of H1 influenza oral tablet vaccine

Risankizumab meets all co-primary endpoints in pivotal phase III psoriasis studies

GlaxoSmithKline patents hSTING modulators

PHSA and UILO divulge new AR modulators

Novel bromodomain inhibitors presented by AbbVie

Regentis Biomaterials identifies new conjugates for bone disorders

Toray Industries divulges antibodies to MCEMP1 for cancer

Japan Tobacco and Torii sign Japanese development and commercialization agreement for JTZ-951

Study confirms nonsedative effects of Neurana's skeletal muscle relaxant tolperisone

Incyte and MacroGenics announce collaboration and license agreement for MGA-012

FDA gives rare pediatric disease designation to Atara Biotherapeutics' ATA-230 for CMV

100% sensitivity of sentinel lymph node detection with [99mTc]Alotech in throat cancer

Enterome completes phase I study of EB-8018

PDL Biopharma submits another unsolicited proposal to acquire Neos Therapeutics

EMA validates mogamulizumab MAA for CTCL

European Commission approves new indication for Firazyr

FDA approves intravenous Varubi for delayed nausea and vomiting associated with chemotherapy

Transgene treats first patient in first-in-human study of TG-6002

Chugai profiles developments of third quarter 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...